Determination of tobramycin serum concentrations in ICU patients treated with SDD: a prospective study.

Determination of tobramycin serum concentrations in ICU patients treated with SDD: a prospective study. - Tobramycin absorption is SDD users.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON43386

Enrollment

Registered

2016-01-28

Start date

2016-03-21

Completion date

Unknown

Last updated

2024-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

profylaxe optreden infecties SDD tobramycine absorption

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Signed informed consent - Patient has to lie on the ICU or Medium Care - ICU - Patient has to use SDD

Exclusion criteria

Exclusion criteria: - Patients that are admitted to the burns IC - Patients concurrently or within 72 hours prior to SDD treatment receiving tobramycin administered parenterally or pulmonary - Patients who aren't treated with the regular schedule

Design outcomes

Primary

Measure	Time frame
The primary endpoint of this study is the achievement of a high (> 1.0 mg / L) tobramycin serum concentration during the use of SDD.	—

Secondary

Measure	Time frame
Secondary endpoints of the study are: Identification of risk factors that contribute to high systemic serum tobramycin concentrations. To this end, we extract data from the patient record in soft chip. With the data extraction the criteria of the National Intensive Care Evaluation (NICE) will be used as much as possible.	—

Countries

Netherlands

Outcome results